Clemens Grassberger

List of Publications by Year
in descending order

49 papers	1,541 citations	361413 20 h-index	330143 37 g-index
52 all docs	52 docs citations	52 times ranked	1674 citing authors

#	Article	IF	Citations
1	Assessing the interactions between radiotherapy and antitumour immunity. Nature Reviews Clinical Oncology, 2019, 16, 729-745.	27.6	183
2	Motion Interplay as a Function of Patient Parameters and Spot Size in Spot Scanning Proton Therapy for Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 86, 380-386.	0.8	168
3	Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. International Journal of Radiation Oncology Biology Physics, 2019, 105, 64-72.	0.8	99
4	Asymptomatic Late-phase Radiographic Changes Among Chest-Wall Patients Are Associated With a Proton RBE Exceeding 1.1. International Journal of Radiation Oncology Biology Physics, 2018, 101, 809-819.	0.8	84
5	Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. Neuro-Oncology, 2021, 23, 284-294.	1.2	78
6	Assessing the Clinical Impact of Approximations in Analytical Dose Calculations for Proton Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1157-1164.	0.8	75
7	Motion mitigation for lung cancer patients treated with active scanning proton therapy. Medical Physics, 2015, 42, 2462-2469.	3.0	74
8	Quantification of Proton Dose Calculation Accuracy in the Lung. International Journal of Radiation Oncology Biology Physics, 2014, 89, 424-430.	0.8	70
9	Roadmap: proton therapy physics and biology. Physics in Medicine and Biology, 2021, 66, 05RM01.	3.0	67
10	Prediction of Treatment Response for Combined Chemo- and Radiation Therapy for Non-Small Cell Lung Cancer Patients Using a Bio-Mathematical Model. Scientific Reports, 2017, 7, 13542.	3.3	56
11	Challenges of radiotherapy: Report on the 4D treatment planning workshop 2013. Physica Medica, 2014, 30, 809-815.	0.7	32
12	Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies. Cancer Research, 2019, 79, 3776-3788.	0.9	32
13	Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1222-1225.	0.8	29
14	A Multi-institutional Comparative Analysis of Proton and Photon Therapy-Induced Hematologic Toxicity in Patients With Medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2021, 109, 726-735.	0.8	29
15	Comparison of weekly and daily online adaptation for head and neck intensity-modulated proton therapy. Physics in Medicine and Biology, 2021, 66, 055023.	3.0	28
16	A tumor-immune interaction model for hepatocellular carcinoma based on measured lymphocyte counts in patients undergoing radiotherapy. Radiotherapy and Oncology, 2020, 151, 73-81.	0.6	26
17	4D blood flow model for dose calculation to circulating blood and lymphocytes. Physics in Medicine and Biology, 2020, 65, 055008.	3.0	25
18	Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy. Radiotherapy and Oncology, 2022, 168, 1-7.	0.6	25

#	Article	IF	Citations
19	Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. International Journal of Radiation Oncology Biology Physics, 2020, 108, 227-241.	0.8	24
20	Automated Monte Carlo Simulation of Proton Therapy Treatment Plans. Technology in Cancer Research and Treatment, 2016, 15, NP35-NP46.	1.9	23
21	Dosimetric Analysis and Normal-Tissue Complication Probability Modeling of Child-Pugh Score and Albumin-Bilirubin Grade Increase After Hepatic Irradiation. International Journal of Radiation Oncology Biology Physics, 2020, 107, 986-995.	0.8	23
22	Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 57-69.	3.7	21
23	Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy. Npj Precision Oncology, 2018, 2, 22.	5.4	20
24	HEDOSâ€"a computational tool to assess radiation dose to circulating blood cells during external beam radiotherapy based on whole-body blood flow simulations. Physics in Medicine and Biology, 2021, 66, 164001.	3.0	20
25	Mathematical Modeling to Simulate the Effect of Adding Radiation Therapy to Immunotherapy and Application to Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1055-1062.	0.8	19
26	Multi-modality management of craniopharyngioma: a review of various treatments and their outcomes. Neuro-Oncology Practice, 2016, 3, 173-187.	1.6	18
27	Differential inflammatory response dynamics in normal lung following stereotactic body radiation therapy with protons versus photons. Radiotherapy and Oncology, 2019, 136, 169-175.	0.6	18
28	Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism inBRAF-Mutated Multiple Myeloma. Clinical Cancer Research, 2021, 27, 6432-6444.	7.0	18
29	Varying relative biological effectiveness in proton therapy: knowledge gaps versus clinical significance. Acta OncolÃ³gica, 2017, 56, 761-762.	1.8	15
30	Fourâ€dimensional Monte Carlo simulations demonstrating how the extent of intensityâ€modulation impacts motion effects in proton therapy lung treatments. Medical Physics, 2013, 40, 121713.	3.0	14
31	Density overwrites of internal tumor volumes in intensity modulated proton therapy plans for mobile lung tumors. Physics in Medicine and Biology, 2018, 63, 035023.	3.0	14
32	Considerations when treating lung cancer with passive scatter or active scanning proton therapy. Translational Lung Cancer Research, 2018, 7, 210-215.	2.8	13
33	A dynamic blood flow model to compute absorbed dose to circulating blood and lymphocytes in liver external beam radiotherapy. Physics in Medicine and Biology, 2022, 67, 045010.	3.0	13
34	Fractionated Lung IMPT Treatments. Technology in Cancer Research and Treatment, 2016, 15, 689-696.	1.9	12
35	Radiation-Induced Lymphopenia Risks of Photon Versus Proton Therapy for Esophageal Cancer Patients. International Journal of Particle Therapy, 2021, 8, 17-27.	1.8	11
36	Biomathematical Optimization of Radiation Therapy in the Era of Targeted Agents. International Journal of Radiation Oncology Biology Physics, 2017, 97, 13-17.	0.8	9

#	Article	IF	Citations
37	Computing proton dose to irregularly moving targets. Physics in Medicine and Biology, 2014, 59, 4261-4273.	3.0	7
38	Prolongation of radiotherapy duration is associated with inferior overall survival in patients with pediatric medulloblastoma and central nervous system primitive neuroectodermal tumors. Pediatric Blood and Cancer, 2020, 67, e28558.	1.5	7
39	Modeling Resistance and Recurrence Patterns of Combined Targetedâ€“Chemoradiotherapy Predicts Benefit of Shorter Induction Period. Cancer Research, 2020, 80, 5121-5133.	0.9	7
40	Physics of Particle Beam and Hypofractionated Beam Delivery in NSCLC. Seminars in Radiation Oncology, 2021, 31, 162-169.	2.2	6
41	Circulating Lymphocyte Counts Early During Radiation Therapy Are Associated With Recurrence in Pediatric Medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1044-1052.	0.8	6
42	A mesh-based model of liver vasculature: implications for improved radiation dosimetry to liver parenchyma for radiopharmaceuticals. EJNMMI Physics, 2022, 9, 28.	2.7	6
43	Predicting Organ-Specific Risk Interactions between Radiation and Chemotherapy in Secondary Cancer Survivors. Cancers, 2017, 9, 119.	3.7	5
44	Pre- and post-treatment image-based dosimetry in ⁹⁰Y-microsphere radioembolization using the TOPAS Monte Carlo toolkit. Physics in Medicine and Biology, 2021, 66, 244002.	3.0	4
45	Dosimetric Modeling of Lymphopenia in Patients With Metastatic Cancer Receiving Palliative Radiation and PD-1 Immune Checkpoint Inhibitors. Advances in Radiation Oncology, 2022, 7, 100880.	1.2	3
46	Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell Therapy. Cancer Immunology Research, 2022, 10, 1055-1068.	3.4	3
47	Three discipline collaborative radiation therapy (3DCRT) special debate: The single most important factor in determining the future of SBRT is immune response. Journal of Applied Clinical Medical Physics, 2019, 20, 6-12.	1.9	1
48	Modelling treatment-response rates. Nature Biomedical Engineering, 2021, 5, 295-296.	22.5	0
49	Predictive Modeling of Survival and Toxicity in Patients With Hepatocellular Carcinoma After Radiotherapy. JCO Clinical Cancer Informatics, 2022, 6, e2100169.	2.1	0